Globe Life Insiders Sell as Q3 Results Land

Globe Life, the McKinney, Texas life and health insurer with a $12.9 billion market cap, delivered Q3 results Wednesday with the stock up 2.2% on the week to $169.72, outpacing the median gain of around 1.2% among its closest peers. The more interesting story sits behind the price action: short interest has climbed to its highest level in at least a year, and senior executives have been selling stock at a steady clip for months.

The positioning picture is notably relaxed on the borrow side but less so on sentiment. Short interest has risen 9% over the past month to 2.7% of the free float, roughly 2.15 million shares, a low absolute level but the highest reading in the ORTEX dataset going back through the year. Availability in the lending pool remains effectively unlimited, with shares lent out representing a fraction of what is available, and the cost to borrow has eased about 9% over the past week to 0.48%, well below the late-September peak near 0.92%. Options traders are not hedging. The put/call ratio is 0.18, essentially flat against its 20-day average, and a long way from the 52-week high of 0.42. The borrow market is loose and options positioning is neutral, which means the building short interest is not yet accompanied by the kind of urgency that precedes a squeeze.

The analyst community remains constructive heading into results. JP Morgan lifted its target to $195 this month while keeping an Overweight rating, and Wells Fargo made a similar small upward move to $191. Morgan Stanley cut its target from $208 to $197 earlier in October but held its Overweight view. The Street's mean target is $193, implying roughly 14% upside from the current price. Bulls point to expected low-double-digit EPS growth driven by premium expansion, investment income growth, and active buybacks, along with a Bermuda reinsurance structure seen as a long-term earnings tailwind. The bear case centres on interest rate sensitivity, credit concerns, and lingering overhang from a short-seller report that pressured the stock's valuation multiples. The P/E is 10.4 times trailing earnings and the EV/EBITDA is 9.3 times, both modest for a company the Street credits with consistent top-line growth.

Insider activity over the past 90 days tells a more cautious story than the analyst consensus. Net selling over that period totals roughly $31.8 million across 176,758 shares. The CEO exercised options and sold nearly 50,000 shares in late July for proceeds of around $9 million. The General Counsel sold stock in early August. The Chief Investment Officer followed in late September, exercising options and selling roughly 10,000 shares at prices just above $169 to $170. None of these trades were declared under a pre-arranged 10b5-1 plan, which removes the mechanical-sale explanation. The pattern is executives converting option grants to cash at market prices, not an unusual practice, but the concentration over three months and the absence of any open-market purchases gives the net figure its weight.

Wikipedia page views registered a z-score of 4.4 against Globe Life's own 90-day history as of late September, pointing to a spike in retail attention around the time the short-seller report resurfaced in investor conversations. That attention does not map to any measurable lead on the company's financials, it is a colour reading on who is looking at the stock, not a forward indicator.

The two most watched variables into the next reporting cycle are whether the Q3 print vindicates the bullish analyst consensus or extends the negative one-day earnings reactions seen in both July prints, when the stock fell between 5.7% and 7.2% the day after results, and whether insider selling continues as option grants are exercised at prices close to where the stock is trading now.